Pulmonary hypertension in COPD

Respiratory Care

Volumn 58, Issue 8, 2013, Pages

  Held, Matthias ^a   Jany, Berthold H ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Clinical trials; COPD; Follow up; Hemodynamics; Pulmonary hypertension; Treatment; Vasoactive drugs

Indexed keywords

BOSENTAN; BUDESONIDE PLUS FORMOTEROL; DIGOXIN; FORMOTEROL; OXYGEN; TIOTROPIUM BROMIDE;

AGED; AIRWAY OBSTRUCTION; ARTICLE; CASE REPORT; CENTRAL SLEEP APNEA SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; EXERCISE TEST; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG WEDGE PRESSURE; MALE; OXYGEN THERAPY; POSITIVE END EXPIRATORY PRESSURE; PULMONARY HYPERTENSION; TRANSLUMINAL CORONARY ANGIOPLASTY;

CLINICAL TRIALS; COPD; FOLLOW-UP; HEMODYNAMICS; PULMONARY HYPERTENSION; TREATMENT; VASOACTIVE DRUGS;

AGED; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; COMORBIDITY; CORONARY ARTERY DISEASE; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PULMONARY DIFFUSING CAPACITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SULFONAMIDES; TREATMENT OUTCOME; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84880687048     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02058     Document Type: Article

References (16)

1. Barberà JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease, advances in pathophysiology and management. Drugs 2009;69(9):1153-1171.
2. Thabut G, Dauriat G, Stern JB, Logeart D, Lévy A, Marrash-Chahla R, Mal H. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127(5):1531-1536.
3. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32(5):1371-1385.
4. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172(2):189-194.
5. Oswald-Mammoser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995;107(5):1193-1198.
6. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE; National Emphysema Treatment Trial (NETT) Research Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002;166(3):314-322.
7. Hale K, Niewoehner D, Cosio MG. Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, and emphysema. Am Rev Respir Dis 1980;122(2): 273-278.
8. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barberà JA, et al; Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-1263.
9. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, et al. Pulmonary hypertension due to chronic lung disease: updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011;154(Suppl 1):S45-S53.
10. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79(6): 2122-2131.
11. Roig Figueroa V, Herrero Perzez A, Abad Lecha E, Ramos Cancelo I, Vielba Ramos D. Bosentan in pulmonary hypertension associated with hypoxaemic lung diseases. Curr Med Res Opin 2007;23(Suppl 2):S49-S53.
12. Valerio G, Bracciale P, Grazia D'Agostino AG. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Disease 2009;3(1):15-21.
13. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32(3):619-628.
14. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-555.
15. Abraham AS, Cole RB, Green ID, Hedworth-Whitty RB, Clarke SW, Bishop JM. Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studied by serial observations during recovery. Circ Res 1969;24(1):51-60.
16. Blanco I, Gimeno E, Muñoz PA, Pizarro S, Gistau C, Rodriguez- Roisin R, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010;181(3):270-278.